Your browser doesn't support javascript.
loading
SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial.
Song, Yuqin; Liu, Yanyan; Li, Zhi-Ming; Li, Lanfang; Su, Hang; Jin, Zhengming; Zuo, Xuelan; Wu, Jianyuan; Zhou, Hui; Li, Kunyan; He, Chuan; Zhou, Jianfeng; Qi, Junyuan; Hao, Siguo; Cai, Zhen; Li, Yijing; Wang, Weiwei; Zhang, Xiaojing; Zou, Jianjun; Zhu, Jun.
Afiliação
  • Song Y; Key Laboratory of Carcinogenesis and Transitional Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
  • Liu Y; Lymphatic Comprehensive Internal Medicine Ward, Henan Cancer Hospital, Zhengzhou, China.
  • Li ZM; Medical Oncology, Sun Yat-sen University Cancer Centre, Guangzhou, China.
  • Li L; Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
  • Su H; The Fifth Medical Centre of the People's Liberation Army General Hospital, Beijing, China.
  • Jin Z; Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Zuo X; Department of Hematopathology, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Wu J; Clinical Trial Centre, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Zhou H; Department of Lymphoma & Hematology (Children's Tumour Centre), Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
  • Li K; Early Clinical Trial Centre, Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
  • He C; Department of Hematopathology, West China Hospital Sichuan University, Chengdu, China.
  • Zhou J; Department of Hematology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.
  • Qi J; Good Clinical Practice Ward, Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China.
  • Hao S; Department of Hematology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Cai Z; Bone Marrow Transplantation Centre, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Li Y; Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals, Shanghai, China.
  • Wang W; Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals, Shanghai, China.
  • Zhang X; Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals, Shanghai, China.
  • Zou J; Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals, Shanghai, China.
  • Zhu J; Key Laboratory of Carcinogenesis and Transitional Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China. Electronic address: zhujun@csco.org.cn.
Lancet Haematol ; 9(7): e493-e503, 2022 Jul.
Article em En | MEDLINE | ID: mdl-35772429
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Hodgkin / Linfoma de Células B / Linfoma Limite: Female / Humans / Male Idioma: En Revista: Lancet Haematol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Hodgkin / Linfoma de Células B / Linfoma Limite: Female / Humans / Male Idioma: En Revista: Lancet Haematol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China